Last reviewed · How we verify
NCT03877029
Long-term Effects of Breast Cancer Treatment
trial in Breast Cancer in 4,487 participants. Completed in 15 December 2025.
13 November 2024
Quick facts
| Lead sponsor | Norwegian Institute of Public Health |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 4,487 |
| Start date | 23 November 2019 |
| Primary completion | 13 November 2024 |
| Estimated completion | 15 December 2025 |
| Sites | 1 location across Norway |
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Norwegian Institute of Public Health
Who can join
Adults 50 to 69, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this project is to generate evidence about quality of life related to side effects of treatment of women with screen-detected versus symptomatic breast cancer. The project will investigate the impact of detection mode (by screening or by symptoms) versus tumor characteristics as a predictor of quality of life among breast cancer survivors. The burden of long-term effects, measured as quality of life at specific points after diagnosis, will be compared between these groups. The results will also be compared with a control group of women, who have attended screening, but never been diagnosed with breast cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway.
Moshina N, Falk RS, Botteri E, Larsen M, et al · · 2022 · cited 13× · PMID 34698976 · DOI 10.1007/s11136-021-03017-7
Verify or expand the search:
- PubMed search for NCT03877029
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Norwegian Institute of Public Health trials
Trials by the same sponsor.
- NCT07442318 — Enabling Environments for Non-communicable Disease Risk Reduction in Ethiopia · NA · not yet recruiting
- NCT07135115 — Targeting Lifestyle to Improve Colorectal Cancer Screening · NA · not yet recruiting
- NCT07355569 — The Effect on Attendance of an SMS Notification Prior to a Scheduled Screening Appointment in BreastScreen Norway · NA · completed
- NCT06324409 — ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening · NA · completed
- NCT06374316 — Air Purifiers in Classrooms for Infection Control - a Pilot Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03877029 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Norwegian Institute of Public Health
- Last refreshed: 9 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03877029.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing